A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.

Campbell, Ciarán; McCormack, Mark; Patel, Sonn; Stapleton, Caragh; Bobbili, Dheeraj; Krause, Roland; Depondt, Chantal; J Sills, Graeme; P Koeleman, Bobby; Striano, Pasquale; Zara, Federico; W Sander, Josemir; Lerche, Holger; S Kunz, Wolfram; Stefansson, Kari; Stefansson, Hreinn; P Doherty, Colin; L Heinzen, Erin; E Scheffer, Ingrid; B Goldstein, David; O'Brien, Terence; Cotter, David; F Berkovic, Samuel; Consortium, EpiPGX; M Sisodiya, Sanjay; Delanty, Norman; L Cavalleri, Gianpiero

doi:10.1111/epi.17228

Public

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.

Shared by NobleBlocks on Jun 1, 2022 • 12:00 AM UTC

Authors:

Ciarán Campbell

Mark McCormack

Sonn Patel

Abstract

OBJECTIVE: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%-20% of people treated with LEV report psychiatric side-effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine t...

Subject

adverse drug reactions

levetiracetam

pharmacogenomics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!